CD274 and non-small cell lung carcinoma: Particularly, the creation of targeted antibodies against the programmed death receptor (PD-1), programmed death-ligand 1 (PD-L1), and the cytotoxic T-lymphocyte-associated protein 4 receptor has significantly improved treatment strategies for metastatic NSCLC, whether used as first-line or second-line therapies, resulting in the unprecedented extended survival of some patients [12].